These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38738384)

  • 61. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
    Perez-Ruiz F; Díaz-Torné C; Carcedo D
    J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
    Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.
    Ghossan R; Aitisha Tabesh O; Fayad F; Richette P; Bardin T
    J Clin Rheumatol; 2024 Mar; 30(2):e46-e53. PubMed ID: 38115182
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
    Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
    Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
    Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
    Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y
    BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
    Li Y; Liu M; Zhang X; Lu Y; Meng J
    Ren Fail; 2019 Nov; 41(1):595-599. PubMed ID: 31267805
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
    Kataoka H; Mochizuki T; Ohara M; Tsuruta Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Kimura K; Hosoya T;
    Sci Rep; 2022 Mar; 12(1):3784. PubMed ID: 35260678
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
    Yan CQ; Liang C; Lan ZR; Su C; Xiong SY; Yang YX; Chen JM; Tang SL; Huang JS; Zhang ZH; Luo MJ; Xiao ZH
    Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11988-12003. PubMed ID: 38164861
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
    Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
    J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.